Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $77.2 (market cap $158.70B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 21.1× Spyre Therapeutics Inc. Common Stock's market cap, and iShares Core MSCI Emerging Markets ETF is more actively traded (9,865,871 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 59 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IEMG | SYRE | |
|---|---|---|
Market Cap | $158.70B | $7.52B |
Volume | 9,865,871 | 1,441,031 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $108.92 |
52-Week Low | $64.72 | $22.18 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $80.22, down 0.51% with a bearish technical signal from moving averages. The ETF faces neutral oscillators but shows support at $79-80 levels. Recent news highlights IEMG's strong performance against peers like SCHE and VWO, with emerging markets attracting record inflows amid dollar weakness and tech sector exposure.
Outlook remains mixed: technical weakness contrasts with fundamental appeal via low-cost emerging market access and 35% trailing returns. Risks include concentration in tech, volatility, and expense ratio disadvantages versus competitors. Analyst sentiment leans cautious due to recent underperformance.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
